Requirements for Power Converters

This paper introduces the requirements for power converters needed for particle accelerators. It describes the role of power converters and the challenges and constraints when powering magnets. The different circuit layouts are presented as well as the operating cycles. The power converter control and high precision definition are also introduced. This paper lists the key circuit parameters to be taken into consideration to properly specify a power converter that can be compiled in a functional specification.Comment: 14 pages, contribution to the 2014 CAS - CERN Accelerator School: Power Converters, Baden, Switzerland, 7-14 May 201

Towards a Phylogenetic Analysis of Galaxy Evolution : a Case Study with the Dwarf Galaxies of the Local Group

Context: The Hubble tuning fork diagram has always been the preferred scheme for classification of galaxies. It is based on morphology only. At the opposite, biologists have long taken into account the genealogical relatedness of living entities for classification purposes. Aims: Assuming branching evolution of galaxies as a 'descent with modification', we show here that the concepts and tools of phylogenetic systematics widely used in biology can be heuristically transposed to the case of galaxies. Methods: This approach that we call "astrocladistics" is applied to Dwarf Galaxies of the Local Group and provides the first evolutionary tree for real galaxies. Results: The trees that we present here are sufficiently solid to support the existence of a hierarchical organization in the diversity of dwarf galaxies of the Local Group. This also shows that these galaxies all derive from a common ancestral kind of objects. We find that some kinds of dIrrs are progenitors of both dSphs and other kinds of dIrrs.We also identify three evolutionary groups, each one having its own characteristics and own evolution. Conclusions: The present work opens a new way to analyze galaxy evolution and a path towards a new systematics of galaxies. Work on other galaxies in the Universe is in progress.Comment: 13 pages 5 figures with 3 online onl

The Self Model and the Conception of Biological Identity in Immunology

The self/non-self model, first proposed by F.M. Burnet, has dominated immunology for sixty years now. According to this model, any foreign element will trigger an immune reaction in an organism, whereas endogenous elements will not, in normal circumstances, induce an immune reaction. In this paper we show that the self/non-self model is no longer an appropriate explanation of experimental data in immunology, and that this inadequacy may be rooted in an excessively strong metaphysical conception of biological identity. We suggest that another hypothesis, one based on the notion of continuity, gives a better account of immune phenomena. Finally, we underscore the mapping between this metaphysical deflation from self to continuity in immunology and the philosophical debate between substantialism and empiricism about identity

Astrocladistics: a phylogenetic analysis of galaxy evolution I. Character evolutions and galaxy histories

This series of papers is intended to present astrocladistics in some detail and evaluate this methodology in reconstructing phylogenies of galaxies. Being based on the evolution of all the characters describing galaxies, it is an objective way of understanding galaxy diversity through evolutionary relationships. In this first paper, we present the basic steps of a cladistic analysis and show both theoretically and practically that it can be applied to galaxies. For illustration, we use a sample of 50 simulated galaxies taken from the GALICS database, which are described by 91 observables (dynamics, masses and luminosities). These 50 simulated galaxies are indeed 10 different galaxies taken at 5 cosmological epochs, and they are free of merger events. The astrocladistic analysis easily reconstructs the true chronology of evolution relationships within this sample. It also demonstrates that burst characters are not relevant for galaxy evolution as a whole. A companion paper is devoted to the formalization of the concepts of formation and diversification in galaxy evolution.Comment: 16 pages, 6 figure

Astrocladistics: a phylogenetic analysis of galaxy evolution II. Formation and diversification of galaxies

This series of papers is intended to evaluate astrocladistics in reconstructing phylogenies of galaxies. The objective of this second paper is to formalize the concept of galaxy formation and to identify the processes of diversification. We show that galaxy diversity can be expected to organize itself in a hierarchy. In order to better understand the role of mergers, we have selected a sample of 43 galaxies from the GALICS database built from simulations with a hybrid model for galaxy formation studies. These simulated galaxies, described by 119 characters and considered as representing still undefined classes, have experienced different numbers of merger events during evolution. Our cladistic analysis yields a robust tree that proves the existence of a hierarchy. Mergers, like interactions (not taken into account in the GALICS simulations), are probably a strong driver for galaxy diversification. Our result shows that mergers participate in a branching type of evolution, but do not seem to play the role of an evolutionary clock.Comment: 14 pages, 4 figure

A statistical mechanics approach to autopoietic immune networks

The aim of this work is to try to bridge over theoretical immunology and disordered statistical mechanics. Our long term hope is to contribute to the development of a quantitative theoretical immunology from which practical applications may stem. In order to make theoretical immunology appealing to the statistical physicist audience we are going to work out a research article which, from one side, may hopefully act as a benchmark for future improvements and developments, from the other side, it is written in a very pedagogical way both from a theoretical physics viewpoint as well as from the theoretical immunology one. Furthermore, we have chosen to test our model describing a wide range of features of the adaptive immune response in only a paper: this has been necessary in order to emphasize the benefit available when using disordered statistical mechanics as a tool for the investigation. However, as a consequence, each section is not at all exhaustive and would deserve deep investigation: for the sake of completeness, we restricted details in the analysis of each feature with the aim of introducing a self-consistent model.Comment: 22 pages, 14 figur

Years of life lost (YLL) from cancer is an important measure of population burden – and should be considered when allocating research funds

Recently, cancer mortality has been compared to research spending by the National Cancer Research Institute (NCRI), whose research budget is approximately £250 million. The analysis shows a mis-match between mortality and research spending. As well as crude mortality rates, other measures of cancer burden should be considered because they contribute additional information. ‘Years of life lost' (YLL) summed over each individual dying after a diagnosis of cancer represents a population-based mortality indicator of the impact of that disease on society. Years of life lost divided by the number of deaths for each cancer site produces an additional statistic, the average years of life lost (AYLL), which is a measure of the burden of cancer to the individual patient. For 17 cancer sites where data are available, four tumour sites have a rather large difference in mortality, comparing YLL to crude mortality. Years of life lost shows the population burden from cancers of the ovary, cervix, and CNS to be rather larger than suggested by crude mortality, despite screening programmes for cervix cancer. Using YLL, the underprovision of funding for lung cancer research is similar to that reported using percentage mortality. Breast cancer and leukaemia receive a relatively higher research spend than the population burden of these cancers, and the spending on leukaemia is quite extreme. Prostate cancer has a low per cent YLL but attracts a moderate amount of research spending. The use of AYLL as an indicator of individual cancer burden considerably changes the ranking of the mortality from different tumours. The mean AYLL is 12.5 years. Prostate cancer has the lowest AYLL, only 6.1 years; brain tumour patients have the highest, at just over 20 years. Comparing AYLL to research spending suggests four ‘Cinderella' cancer sites with high individual cancer burden but low research spending: CNS tumours, cervix and kidney cancers, and melanoma. Breast cancer and leukaemia have roughly average AYLL but a considerable excess of research spending. YLL emphasises the discrepancy between research spending and mortality, and may be helpful for decisions concerning research support. Avearage years of life lost measures the burden to individual patients and may be helpful where individuals' needs are relevant, such as palliative care. As well as crude mortality, more subtle and comprehensive calculations of mortality statistics would be useful in debates on research funding and public health issues

Cripto: Expression, epigenetic regulation and potential diagnostic use in testicular germ cell tumors

Type II germ cell tumors arise after puberty from a germ cell that was incorrectly programmed during fetal life. Failure of testicular germ cells to properly differentiate can lead to the formation of germ cell neoplasia in situ of the testis; this precursor cell invariably gives rise to germ cell cancer after puberty. The Nodal co-receptor Cripto is expressed transiently during normal germ cell development and is ectopically expressed in non-seminomas that arise from germ cell neoplasia in situ, suggesting that its aberrant expression may underlie germ cell dysregulation and hence germ cell cancer. Here we investigated methylation of the Cripto promoter in mouse germ cells and human germ cell cancer and correlated this with the level of CRIPTO protein expression. We found hypomethylation of the CRIPTO promoter in undifferentiated fetal germ cells, embryonal carcinoma and seminomas, but hypermethylation in differentiated fetal germ cells and the differentiated types of non-seminomas. CRIPTO protein was strongly expressed in germ cell neoplasia in situ along with embryonal carcinoma, yolk sac tumor and seminomas. Further, cleaved CRIPTO was detected in media from seminoma and embryonal carcinoma cell lines, suggesting that cleaved CRIPTO may provide diagnostic indication of germ cell cancer. Accordingly, CRIPTO was detectable in serum from 6/15 patients with embryonal carcinoma, 5/15 patients with seminoma, 4/5 patients with germ cell neoplasia in situ cells only and in 1/15 control patients. These findings suggest that CRIPTO expression may be a useful serological marker for diagnostic and/or prognostic purposes during germ cell cancer management